NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 06/09/2026 13:56
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,137.51 mln
Float221 mln
Earnings Date07/30/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-9.63
Highly reliable
Relative Strength
61
/ 100
Outperforming
Debt / Equity
-1.48
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
BioCryst Pharmaceuticals is a drug development company based in Durham, North Carolina, focused on creating treatments for rare and serious medical conditions. Its main products include ORLADEYO, a pill for hereditary angioedema, and RAPIVAB, an intravenous flu treatment. The company also has several drugs in clinical trials targeting conditions such as Netherton syndrome, diabetic eye disease, and atopic dermatitis. BioCryst works with a range of partners including pharmaceutical companies, government health agencies, and academic institutions to advance its research.
